Olga Gonzalez-Byrne
Family · Morris Plains, NJNPI 1336516582
Payments from drug & device makers
Across 96 payments — averaging $42.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$877
- GSK$639
- Teva Pharmaceuticals USA, Inc.$423
- Novo Nordisk$328
- E.r. Squibb & Sons, L.L.C.$239
- Boehringer Ingelheim$210
- plus $1K from 16 others
What the payments were for
- Food & beverage$4,094100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 8 | $877 |
| GSK | 17 | $639 |
| Teva Pharmaceuticals USA, Inc. | 4 | $423 |
| Novo Nordisk | 16 | $328 |
| E.r. Squibb & Sons, L.L.C. | 2 | $239 |
| Boehringer Ingelheim | 7 | $210 |
| Axsome Therapeutics, Inc. | 2 | $209 |
| AstraZeneca | 4 | $163 |
| Sanofi-aventis U.S. LLC | 3 | $136 |
| Supernus Pharmaceuticals, Inc. | 1 | $125 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $125 |
| Corium, LLC | 1 | $114 |
| Redhill Biopharma Inc. | 7 | $94 |
| Merck | 6 | $86 |
| AbbVie | 2 | $85 |
| Lilly USA, LLC | 5 | $71 |
| Pfizer | 3 | $52 |
| Neurocrine Biosciences, Inc. | 1 | $44 |
| Althera Pharmaceuticals LLC | 3 | $42 |
| Kaleo, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
| Next Science LLC | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$480
- REXULTI$478
- ABILIFY MAINTENA$239
- COBENFY$239
- Austedo XR$221
- CAPLYTA$125
- QELBREE$125
- BREZTRI$125
- JARDIANCE$124
- ABILIFY ASIMTUFII$122
- UZEDY$120
- Auvelity$119
- Azstarys$114
- RYBELSUS$106
- SOLIQUA 100/33$106
How this compares
$4,094 in reported general payments places this provider in the 90th percentile of 2,692 family providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 36 | $55,091 |
| VraylarCariprazine Hcl | 12 | $18,870 |
| Olanzapine | 28 | $585 |
| Hydroxyzine Hcl | 14 | $353 |
| Gabapentin | 34 | $340 |
| Quetiapine Fumarate | 21 | $220 |
| Amitriptyline Hcl | 12 | $212 |
| Escitalopram Oxalate | 50 | $201 |
| Risperidone | 13 | $172 |
| Clonazepam | 31 | $170 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $114 |
| Sertraline Hcl | 55 | $99 |
| Lamotrigine | 26 | $89 |
| Trazodone Hcl | 24 | $58 |
| Lorazepam | 13 | $56 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $877 | $55,09136 claims |
| AbbVieVraylar | $85 | $18,87012 claims |
| Lilly USA, LLCOlanzapine | $71 | $58528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,692 family providers in New Jersey.
Other family in Morris Plains
- Jennifer DemaioMorristown$412K
- Kara TrlicaCranbury$186K
- Nicole BauerParamus$161K
- Angie GarciaWest New York$161K
- China BattistaWall Township$142K
- Nancy EisenbergerVoorhees$82K
- Jennifer AbitabiloGlen Ridge$54K
- Megan FiloramoMorristown$53K
- Shawn DenningToms River$29K
- Kimberly ClementeEatontown$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.